Search Within

Shugaku Takeda

Formats
  1. Journal Article (13)
  2. Meeting Abstract (5)
Groups
  1. Sloan Kettering Institute Postdocs (18)
  2. Department of Pathology and Laboratory Medicine (17)
  3. GSK Faculty (17)
  4. Human Oncology and Pathogenesis Program (17)
  5. Department of Medicine (9)
  6. Genitourinary Oncology Service (9)

More Groups

People
  1. James Hsieh (15)
  2. Emily Cheng (14)
  3. Han Liu (12)
  4. Abraham Hakimi (9)
  5. Martin Voss (8)
  6. Robert Motzer (8)

More People

Years
  1. 2021 (1)
  2. 2017 (2)
  3. 2015 (2)
  4. 2014 (1)
  5. 2013 (7)
  6. 2012 (5)
Publications
  1. Cancer Research (3)
  2. BJU International (2)
  3. Cell Reports (2)
  4. Clinical Cancer Research (2)
  5. Journal of Clinical Investigation (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (5)
  2. Cell Press (3)
  3. American Society for Clinical Investigation (2)
  4. American Society of Clinical Oncology (2)
  5. Wiley Blackwell (2)
  6. Amer Soc Clinical Investigation Inc (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and the KIRC TCGA research network
    Journal Article

    Hakimi, A. A.; Ostrovnaya, I.; Reva, B.; Schultz, N.; Chen, Y. B.; Gonen, M.; Liu, H.; Takeda, S.; Voss, M. H.; Tickoo, S. K.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma
    Journal Article

    Hakimi, A. A.; Chen, Y. B.; Wren, J.; Gonen, M.; Abdel-Wahab, O.; Heguy, A.; Liu, H.; Takeda, S.; Tickoo, S. K.; Reuter, V. E.; more...
    European Urology (2013)

    Fulltext@MSK | Save
  • PUMA and BIM are required for oncogene inactivation-induced apoptosis
    Journal Article

    Bean, G. R.; Ganesan, Y. T.; Dong, Y.; Takeda, S.; Liu, H.; Chan, P. M.; Huang, Y.; Chodosh, L. A.; Zambetti, G. P.; Hsieh, J. J. D.; more...
    Science Signaling (2013)

    Fulltext@MSK | Save
  • Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Scott, S. N.; Takeda, S.; Liu, H.; Chen, Y.; Motzer, R. J.; Berger, M. F.; Hsieh, J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Next-generation sequencing reveals genomic determinants of long-term response to mTOR inhibitors in patients with advanced RCC
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Brannon, A. R.; Scott, S.; Takeda, S.; Liu, H.; Chen, Y.; Motzer, R. J.; Berger, M. F.; Hsieh, J. J.
    BJU International (2012)

    Fulltext@MSK | Save
  • Tumor suppressor screens of 3p chromatin modulators link BAP1 mutations to poor clinical outcomes in clear cell renal cell carcinoma
    Meeting Abstract

    Hakimi, A. A.; Chen, Y. B.; Wren, J.; Ostrovnaya, I.; Gonen, M.; Abdel-Wahab, O.; Heguy, A.; Liu, H.; Takeda, S.; Tickoo, S. K.; more...
    BJU International (2012)

    Fulltext@MSK | Save
  • Targeting Taspase1 for cancer therapy - Response
    Journal Article

    Chen, D. Y.; Takeda, S.; Oyama, T.; Hsieh, J. J.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • A pharmacologic inhibitor of the protease taspase1 effectively inhibits breast and brain tumor growth
    Journal Article

    Chen, D. Y.; Lee, Y.; Van Tine, B. A.; Searleman, A. C.; Westergard, T. D.; Liu, H.; Tu, H. C.; Takeda, S.; Dong, Y.; Piwnica-Worms, D. R.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save